Cited by 180Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNerve injury and regeneration

Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients

Open access
Laske, Christoph, Stellos, Konstantinos, Hoffmann, Nadine, Stransky, Elke, Straten, Guido, Eschweiler, Gerhard W., Leyhe, Thomas·2011·The International Journal of Neuropsychopharmacology

Abstract

The neurotrophin brain-derived neurotrophic factor (BDNF) plays a critical role in neuronal survival, synaptic plasticity, and memory. Several recent studies have demonstrated altered BDNF serum levels in Alzheimer's disease (AD) patients. However, the association of BDNF serum levels with the rate of cognitive decline in AD patients is still unclear. We demonstrate that BDNF serum levels are significantly decreased in AD patients with fast cognitive decline [decrease of Mini-Mental State Examination (MMSE) score >4/yr; n=12] compared to AD patients with slow cognitive decline (decrease of MMSE score ≤4/yr, n=28) and show a significant correlation with the rate of cognitive decline during 1 yr follow-up. These results suggest that higher BDNF serum levels are associated with a slower rate of cognitive decline in AD patients. Further longitudinal studies are necessary to elucidate the kinetics and the potential role of serum BDNF as a surrogate marker of disease progression in AD patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1461145710001008

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In Alzheimer's disease patients, higher serum BDNF concentrations are associated with less cognitive decline after 1 year, and this effect is more pronounced in more severe disease stages.

    “AD patients with higher serum concentrations of BDNF showed less cognitive decline after 1 year; this effect was more pronounced in the more severe stages of the disease [142, 143].”
  • BDNF might be a predictor for the rate of disease progression in Alzheimer's disease.

    “These studies suggest that BDNF might be a predictor for the rate of disease progression in AD.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Laske, C., Stellos, K., Hoffmann, N., Stransky, E., Straten, G., Eschweiler, G. W., & Leyhe, T.
Affiliations
University of Tübingen (DE)
Corresponding author
Laske, Christoph
Venue
The International Journal of Neuropsychopharmacology
Published
2010-09-22
Volume
14
Issue
03
Pages
399-404
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2103119955
Cited by
180
References
30
Citations by year
2026: 8 · 2025: 16 · 2024: 7 · 2023: 13 · 2022: 10 · 2021: 13 · 2020: 17 · 2019: 12 · 2018: 10 · 2017: 9 · 2016: 13 · 2015: 11 · 2014: 15 · 2013: 10 · 2012: 11
FWCI
5.67
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords
brain-derived neurotrophic factor, serum BDNF, Alzheimer's disease, cognitive decline, Mini-Mental State Examination, biomarkers, disease progression, neurotrophins
MeSH terms
Alzheimer Disease, Cognition, Cognition Disorders, Female, Humans, Male, Neuropsychological Tests, Time Factors, Biomarkers, Disease Progression, Brain-Derived Neurotrophic Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review